All Articles

Continuous glucose monitoring in insulin-treated diabetes beyond glycemic control and towards precision metabolic care

Follistatin-like 1 and galectin-1 as potential exerkines: a cross-study evaluation of tissue attribution and implications for metabolic disease

Emerging pharmacological treatment options for MASLD/MASH

Obesity-induced mesenchymal stem cell dysfunction: from molecular mechanisms to therapeutic strategies

Combined lifestyle and type 2 diabetes mellitus among women with a history of GDM or HDP

Orforglipron versus oral semaglutide in type 2 diabetes, clinical implications of the ACHIEVE-3 trial

Tirzepatide for OSA and obesity: do we know the effect on cardiometabolic outcome?

Why wait? Early combination therapy in diabetic kidney disease: lessons from CONFIDENCE

MASLD epidemiology, natural history and diagnosis

Insulin physiology and metabolic control: current concepts and perspectives

Triglyceride-glucose waist-to-weight index and bone microarchitecture in type 2 diabetes: a machine-learning and regression analysis

Extracellular vesicle-mediated communication in diabetic cardiomyopathy: cellular mechanisms, metabolic remodeling, and emerging therapeutic strategies

Finerenone in type 1 diabetes and chronic kidney disease

Urinary extracellular vesicles detect altered renal circulation in human obesity

Multimorbidity comes to roost: insights from the LiverScreen project on the future burden of metabolic liver disease

Correction: Short-term L-arabinose administration alleviates MASLD by remodeling gut microbiota and activating hepatic ATF5-dependent mitochondrial unfolded protein response

Determinants of plasma branched-chain amino acids and associations with cardiometabolic biomarkers and proteomic signatures

Associations of cardiovascular-kidney-metabolic syndrome stage with trabecular bone score and bone mineral density